Page last updated: 2024-12-10

2-({2-[4-(4-Fluorophenyl)piperazino]-2-oxoethyl}sulfanyl)acetic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

The chemical name you provided, **2-({2-[4-(4-Fluorophenyl)piperazino]-2-oxoethyl}sulfanyl)acetic acid**, describes a molecule that belongs to a class of compounds known as **piperazine derivatives**.

**Structure:**

* **Piperazine ring:** This is a six-membered heterocyclic ring containing two nitrogen atoms.
* **4-Fluorophenyl group:** This is a phenyl ring (benzene ring) substituted with a fluorine atom at the para position.
* **2-oxoethyl group:** This is a two-carbon chain with a carbonyl group (C=O) at one end.
* **Sulfanyl group:** This is a sulfur atom directly linked to a carbon atom.
* **Acetic acid group:** This is a carboxyl group (COOH) attached to a two-carbon chain.

**Significance in Research:**

Piperazine derivatives, including the one you described, are often explored in research because they exhibit a wide range of biological activities. These activities are often attributed to their ability to interact with various receptors and enzymes in the body.

Here are some potential areas where this specific molecule could be relevant for research:

* **Anti-inflammatory:** Piperazine derivatives have been investigated for their potential anti-inflammatory properties. They may inhibit the production of inflammatory mediators like cytokines and prostaglandins.
* **Antioxidant:** Some piperazine derivatives possess antioxidant activity, which might protect cells from damage caused by free radicals.
* **Neuropharmacological:** Piperazine derivatives have shown potential as neuroprotective agents, potentially useful in treating conditions like Parkinson's disease and Alzheimer's disease.
* **Antibacterial:** Research suggests that some piperazine derivatives exhibit antibacterial activity against various bacterial strains.
* **Anticancer:** Certain piperazine derivatives have been explored for their potential to inhibit the growth of cancer cells.

**Important Note:** It is crucial to remember that the specific compound you described is not a well-established drug and its precise biological effects are still under investigation. Further research is needed to understand its safety, efficacy, and potential therapeutic applications.

**To learn more about the specific research being conducted on this compound, you can search for its name or its chemical structure in databases such as PubMed, SciFinder, or Google Scholar.**

Cross-References

ID SourceID
PubMed CID2812661
CHEBI ID170061

Synonyms (16)

Synonym
2-({2-[4-(4-fluorophenyl)piperazino]-2-oxoethyl}sulfanyl)acetic acid
2-[2-[4-(4-luorophenyl)piperazin-1-yl]-2-oxoethyl]sulanylacetic acid
CHEBI:170061
OPREA1_592431
SR-01000642154-1
HMS1663F15
2-[2-[4-(4-fluorophenyl)piperazin-1-yl]-2-oxoethyl]sulfanylacetic acid
AKOS005094424
CCG-52957
551931-35-2
5R-0637
2-({2-[4-(4-fluorophenyl)piperazin-1-yl]-2-oxoethyl}sulfanyl)acetic acid
2-((2-(4-(4-fluorophenyl)piperazino)-2-oxoethyl)sulfanyl)acetic acid
2-((2-(4-(4-fluorophenyl)piperazin-1-yl)-2-oxoethyl)thio)acetic acid
CS-0364010
mfcd02186918
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
piperazines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.13 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]